morbidity and mortality conference maria monina t. clauna, m.d. may 24, 2007 makati medical center
TRANSCRIPT
![Page 1: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/1.jpg)
Morbidity and Mortality Morbidity and Mortality ConferenceConference
Maria Monina T. Clauna, M.D. May 24, 2007
Makati Medical Center
![Page 2: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/2.jpg)
General DataGeneral Data
N.M.41 y.o.
G3P2 (2002)PU 37 3/7 wks AOG by LMP
![Page 3: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/3.jpg)
CHIEF COMPLAINTCHIEF COMPLAINT
![Page 4: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/4.jpg)
History of Present IllnessHistory of Present Illness
3 days PTA RUQ painOB consult
GI referralImp: Cholelithiasis vs.
acid peptic diseaseDx: HBT UTZTx: Pinaverium & Al-Mg
OH
![Page 5: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/5.jpg)
History of Present IllnessHistory of Present Illness
Few hours PTA
Progressive RUQ painER consult
AdmissionAdmission
![Page 6: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/6.jpg)
Review of SystemsReview of Systems
No fever, weakness, anorexia, weight lossNo headache, BOV, dizziness, sore throatNo cough, colds, dyspneaNo chest pain, palpitations, easy fatigability, orthopnea, PNDNo hypogastric pain, dysuria, hematuria, urinary frequencyNo easy bruisability nor bleeding tendenciesNo edema
![Page 7: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/7.jpg)
Past Medical HistoryPast Medical History
No DM, HPN, Bronchial asthma, PTB, acid peptic diseaseNo allergies to food nor drugsNo previous surgeries
![Page 8: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/8.jpg)
Menstrual & OB-GYN HistoryMenstrual & OB-GYN History
Menarche: 13 y/o, 4-6 days, every 30 days, 5 ppd no dysmenorrheaG1 1990, LFT, male, 6.1 lbs., SVD, in Cavite, no complicationsG2 1996, LFT, male, 7.1 lbs., SVD, in Cavite, no complicationsG3 unremarkable PNCUs; normal BP monitorings & U/A, meds: Mulitivitamins & FeS04No artificial family planning method used
![Page 9: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/9.jpg)
Family Medical HistoryFamily Medical History
DM – father No hypertension, asthma, PTB, CVA, CV disease, cancer, hematologic disorder
![Page 10: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/10.jpg)
Personal Social HistoryPersonal Social History
HousewifeNon-smokerNon-alcoholic beverage drinkerNo regular exercise, does the household chores
![Page 11: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/11.jpg)
Physical ExaminationPhysical Examination
Conscious, coherent, ambulatory, not in cardio-respiratory distressBP 110/80 HR 85 RR 19 T36.8 CHt. 4’11” Wt. 64.2 kgs. BMI 28.6 No skin dermatoses nor jaundicePink palpebral conjunctiva, anicteric sclera; no lymphadenopathy, neck vein engorgment nor thyromegaly
![Page 12: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/12.jpg)
Physical ExaminationPhysical Examination
Symmetrical chest expansion, no rib retractions, clear breath soundsAdynamic precordium, normal rate and regular rhythm, no murmursGlobular abdomen, striae gravidarum, normoactive bowel sounds, tense, w/ direct RUQ tenderness, (-) Murphy’s sign, FHT 142 bpmNo costovertebral angle tenderness
![Page 13: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/13.jpg)
Physical ExaminationPhysical Examination
Extremities:Full equal pulses, pink nail bedsNo cyanosis, edema nor varicosities
Internal Exam:Admits fingertip, closed cervix, intact int. Os
![Page 14: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/14.jpg)
Salient FeaturesSalient Features
41 y/o, female, obeseMultigravid, PU 37 3/7 wks. AOG by LMPProgressive RUQ paindirect RUQ tenderness
![Page 15: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/15.jpg)
Admitting ImpressionAdmitting Impression
T/c Cholelithiasis vs. Acid Peptic Disease G3P2 (2002), Pregnancy Uterine 37 3/7 weeks AOG by LMP, not in labor
![Page 16: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/16.jpg)
Course in the HospitalCourse in the Hospital
![Page 17: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/17.jpg)
Upon AdmissionUpon Admission
GI referralHepatobiliary UTZ: cholelithiases w/ cholecystitis
Underwent elective primary LTCS, delivered a live baby girl & followed by open cholecystectomy w/ IOC
Histopathologic findings: acute cholecystitis w/ 27 cholelithiasis
![Page 18: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/18.jpg)
Problem: PulmonaryProblem: Pulmonary
S>1st HD: (+)DOB while on BT, I&0 2530/900cc
O> BP 110/70, HR 110, RR of 40, T 37.2°C,
O2 sats 96-97% on room air, distended neck veins JVP 7cmH2O & bibasal rales
A> T/c pulmonary congestion probably secondary to fluid overload, r/o pulmonary embolism
![Page 19: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/19.jpg)
Problem: PulmonaryProblem: Pulmonary
P> Oxygen at 2LPM/NC
Given FurosemideNormal CXR Normal ECG ABG showed mild hypoxemiaD-dimer = 1000 ng/ml
![Page 20: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/20.jpg)
Problem: PulmonaryProblem: Pulmonary
P> Referred to Pulmonology
Enoxaparin 40 mg SQ BIDPulmonary CT Angiography: pulmonary embolism, pneumonia not ruled out
![Page 21: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/21.jpg)
Problem: PulmonaryProblem: Pulmonary
S> 4th HD: (+) DOB
O> BP 120/90, HR 120, RR of 30, T 37.7°C O2 sats 87% on room air and clear BS
A> t/c Hospital acquired pneumonia
P> Oxygen at 2LPM/NCRepeat CBC: leukocytosis
Repeat CXR: atelectasis vs. pneumoniaRepeat ABG was normalCefuroxime & ClindamycinDecreasing WBC count
![Page 22: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/22.jpg)
Problem: HematologicProblem: Hematologic
S> 6th HD: (+) gross hematuria
CBC: anemia Crea 0.7
O> no hypogastric nor CVA tenderness
A> Hematuria 2° to LMWH
![Page 23: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/23.jpg)
Problem: HematologicProblem: Hematologic
P> UTZ-KUB: urinary bladder hematoma & normal kidneysUrology referral (blood clots in urine)Cystogram: NormalCystoscopy: Urinary bladder bleeding & hematoma; blood clots evacuation & CystoclysisTransfused 1 ‘u’ PRBC & repeat CBCEnoxaparin was discontinuedIVC filter placement
![Page 24: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/24.jpg)
Upon DischargeUpon Discharge
24th HD:Resolution of hematuriaPatient was sent home stable.THM:
Nexium 40mg/tab ODLaxoberal 45cc gtts
![Page 25: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/25.jpg)
Final DiagnosisFinal Diagnosis
Pulmonary EmbolismAnemia secondary to blood loss secondary to urinary bladder hematomaG3P3 (3003); s/p Primary LTCS, delivered a live baby girl, APGAR 7/9, 3.1 kgs. (01/19/07)s/p Open Cholecystectomy w/ IOC ( 1/19/07)s/p Cystoscopy (01/27/07)s/p IVC filter placement (01/31/07)
![Page 26: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/26.jpg)
DISCUSSIONDISCUSSION
![Page 27: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/27.jpg)
Pulmonary EmbolismPulmonary Embolism
common disorder, with substantial associated morbidity and mortalitya nonspecific clinical presentationoften poses a significant diagnostic challengeDyspnea – most frequent symptomTachypnea – most frequent sign
Hlavac,M., MBChB, FRACP. Latex Enhanced Immunoassay D-dimer and Blood GasesCan Exclude Pulmonary Embolism in Low-Risk Patients Presenting to an
Acute Care Setting.CHEST 2005; 128: 2183-2189
![Page 28: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/28.jpg)
![Page 29: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/29.jpg)
Pulmonary EmbolismPulmonary Embolism
Risk Factors:- long air travel- obesity- cigarette smoking- oral contraceptives- pregnancy- post menopausal hormone replacement- trauma- medical conditions (Cancer, Hypertension, COPD etc.)
- Thrombophilia
![Page 30: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/30.jpg)
Pulmonary EmbolismPulmonary Embolism
Increased pulmonary vascular resistanceImpaired gas exchangeAlveolar hyperventilationIncreased airway resistanceDecreased pulmonary compliance
![Page 31: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/31.jpg)
![Page 32: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/32.jpg)
DiagnosisDiagnosis
![Page 33: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/33.jpg)
![Page 34: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/34.jpg)
Arterial Blood GasArterial Blood Gas
ABG measurements & pulse oximetry have a limited role in diagnosing PE Usually reveal hypoxemia, hypocapnia & respiratory alkalosis
Rodger, MA, Carrier, M, Jones, GN, et al. Diagnostic value ofarterial blood gas measurement in suspected pulmonary
embolism. Am J Respir Crit Care Med 2000; 162:2105.
![Page 35: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/35.jpg)
![Page 36: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/36.jpg)
D – dimer AssayD – dimer Assay
Sensitivity of 96 - 100%
Highest negative predictive value when used to exclude VTE & PE in younger patients without associated co-morbidity/ history of VTE & w/ short duration of sxs
Annals of Family Medicine. Vol.5, No.1, January/February 2007
![Page 37: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/37.jpg)
V/Q ScanV/Q Scan
High probabilitySegmental/lobar perfusion defect w/ normal ventilation
Low probability Perfusion defect w/ matched ventilation abnormality
![Page 38: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/38.jpg)
V/Q ScanV/Q Scan
Sensitivity of 40%
Unfortunately, the combination of clinical & V/Q scan probability found in most patients (up to 72%) has a diagnostic accuracy of only 15-86%
Value of the ventilation/perfusion scan in acute pulmonary embolism. Results
of the prospective investigation of pulmonary embolism diagnosis(PIOPED). The PIOPED Investigators. JAMA 1990; 263:2753.
Cross, J.J.L. A Randomized Trial Scintigraphy for the of Spiral CT and Ventilation Perfusion Diagnosis of Pulmonary Embolism.
Clinical Radiology 1998; 53: 177-182
![Page 39: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/39.jpg)
Pulmonary AngiographyPulmonary Angiography
Sensitivity of 90%Specificity of 95%Previously 'the gold standard'Underused because of a 5% morbidity & 2% mortalityComplications:
1) catheter insertion2) contrast reactions3) cardiac arrhythmia4) respiratory insufficiency
Cross, J.J.L. A Randomized Trial Scintigraphy for the of Spiral CT and Ventilation Perfusion Diagnosis of Pulmonary Embolism.
Clinical Radiology 1998; 53: 177-182Annals of Family Medicine. Vol.5, No.1, January/February 2007
![Page 40: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/40.jpg)
Pulmonary CT Angiogram Pulmonary CT Angiogram
Sensitivity of 90%Specificity of 89 - 95% Advantages:
1) non-invasive2) less operator dependent4) images the lungs, mediastinum and
pleura5) reveal non-embolic lesions
presenting w/ symptoms identical to PE w/c are likely to produce non-diagnostic VQ scan
Cross, J.J.L. A Randomized Trial Scintigraphy for the of Spiral CT and Ventilation Perfusion Diagnosis of Pulmonary Embolism.
Clinical Radiology 1998; 53: 177-182Annals of Family Medicine. Vol.5, No.1, January/February 2007
![Page 41: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/41.jpg)
![Page 42: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/42.jpg)
![Page 43: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/43.jpg)
![Page 44: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/44.jpg)
![Page 45: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/45.jpg)
TreatmentTreatment
![Page 46: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/46.jpg)
HeparinHeparin
Heterogeneous mixture of sulfated mucopolysaccharides.MOA: Accelerates inhibition of clotting factor proteases (Factor II, IX, X, XI & XII) by Antithrombin III to form equimolar stable complexes
![Page 47: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/47.jpg)
EnoxaparinEnoxaparin
Low molecular weight heparinMOA: Inhibits more specifically Factor Xa by binding w/ ATIII with the same pentasaccharide sequence as UFHNot generally monitored except in renal insufficiency & pregnancyTherapeutic level = 0.5-1.0 unit/mLGiven at 1 mg/kg per dose SQ BID or
1.5 mg/kg SQ OD
![Page 48: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/48.jpg)
Advantages of EnoxaparinAdvantages of Enoxaparin
Superior bioavailabilityLimited non-specific bindingNon-dose-dependent half-livesNo need for laboratory monitoringAssociated with less HIT & osteopeniaLower mortalityFewer recurrent thrombotic eventsLess major bleeding
van Dongen, CJ, et al. Fixed dose subcutaneous low molecularweight heparinsversus adjusted dose unfractionated heparinfor venous thromboembolism
Cochrane Database Syst Rev 2004.
![Page 49: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/49.jpg)
77thth ACCP Guidelines ACCP Guidelines
Grade 1 recommendations – strong indication that the benefits do/don’t outweigh risks, burden & costs
Grade 2 suggests that individual patients’ values may lead to different choices
Geerts, W.H. Prevention of Venous Thromboembolism (The7th ACCPConference on Antithrombotic and Thrombolytic
Therapy).CHEST. 2004; 126: 338S-400S
![Page 50: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/50.jpg)
77thth ACCP Guidelines ACCP Guidelines
Acutely ill medical patientsActive cancerPrevious VTESepsisAcute neurologic diseaseInflammatory bowel diseaseRecommendation: prophylaxis w/ LDUH (Grade 1A) or LMWH (Grade 1A)
![Page 51: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/51.jpg)
77thth ACCP Guidelines ACCP Guidelines
When there is a contraindication to anticoagulant prophylaxis
Recommendation: use of mechanical prophylaxis with GCS or IPC (Grade 1C)
![Page 52: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/52.jpg)
77thth ACCP Guidelines ACCP Guidelines
Recommend against the use of aspirin alone as prophylaxis against VTE for any patient group (Grade 1A)
Prophylaxis with low dose unfractionated heparin 2-3x daily for major obstetric & gynecololgic surgery
![Page 53: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/53.jpg)
77thth ACCP Guidelines ACCP Guidelines
Long distance travel (flights of 6 h duration)avoidance of constrictive clothing around the lower extremities or waistavoidance of dehydrationfrequent calf muscle stretching
(Grade 1C)
![Page 54: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/54.jpg)
77thth ACCP Guidelines ACCP Guidelines
Properly fitted, below-knee GCS providing 15-30 mmHg of pressure at the ankle (Grade 2B)Single prophylactic dose of LMWH injected prior to departure (Grade 2B)Recommend against the use of aspirin for VTE prevention associated w/ travel (Grade 1B)
![Page 55: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/55.jpg)
Emerging AnticoagulantsEmerging Anticoagulants
Weitz, J.I. Emerging Anticoagulants for the Treatment of Thromboembolism.Thromb Haemostat. July 2006. 96: 274-284
![Page 56: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/56.jpg)
Duration of AnticoagulationDuration of Anticoagulation
Patients w/ a 1st PE or DVT & an irreversible risk factor (protein S deficiency), should be treated for at least 6-12 months and indefinite anticoagulation should be considered.
Buller, HR, Agnelli, G, Hull, RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
2004; 126:401S.
![Page 57: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/57.jpg)
Duration of Anticoagulation for Venous Thromboembolism
EventDuration of
Anticoagulation
Situational DVT 6 wks. - 3 mos.
Idiopathic DVT 3-6 mos. (minimum)
Recurrent idiopathic DVT 12 mos. (minimum)
VTE w/ ongoing risk factors Long term/ indefinite
Pulmonary embolism 6 mos. (minimum)
Massive pulmonary embolism long term/ indefinite
![Page 58: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/58.jpg)
Inferior Vena Caval FilterInferior Vena Caval Filter
Indications:1) Absolute contraindication to
anticoagulation (eg, active bleeding) 2) Recurrent PE during adequate
anticoagulant therapy 3) Complication of anticoagulation (eg,
severe bleeding)
![Page 59: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/59.jpg)
Inferior Vena Caval FilterInferior Vena Caval Filter
Complications:1) related to the insertion process
(bleeding/ venous thrombosis at the insertion site)
2) Filter misplacement3) Filter migration 4) Filter erosion & perforation of the IVC
wall5) IVC obstruction due to filter
thrombosis
![Page 60: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/60.jpg)
Inferior Vena Caval FilterInferior Vena Caval FilterFilter insertion was successful in 98.6% of patients and resulted in an immediate complication in 11.8%.The median duration of filter implantation was 166 days. 17.0% (37 of 217 patients) had at least one venous thromboembolic event.Filter retrieval was attempted in 25.3% of patients after a median of 51 days.Removal was successful at the first attempt in 92.7% of patients.Conclusion: The filter could be easily inserted and successfully removed up to 1 year after insertion.
S. Laporte, et al. A Prospective Long-term Study of 220 PatientsWith a Retrievable Vena Cava Filter for Secondary Prevention of
Venous Thromboembolism CHEST. 2007;131;223-229
![Page 61: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/61.jpg)
Thank you!Thank you!
![Page 62: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/62.jpg)
Thrombin Factor XIII
Fibrinogen Fibrin Cross-linked fibrin
Plasmin
Fibrin degradation products (D-
Dimer)
D - dimer AssayD - dimer Assay
![Page 63: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/63.jpg)
Coagulation PathwayCoagulation Pathway
Heparin
![Page 64: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/64.jpg)
Differential DiagnosisDifferential Diagnosis
Acute Myocardial InfarctionPneumonia, bronchitis, exacerbation of asthma or chronic obstructive pulmonary diseaseCongestive Heart FailurePneumothoraxAnxiety
![Page 65: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/65.jpg)
Barry, P., et al. Current Diagnosis of Venous Thromboembolism in Primary Care: A Clinical Practice Guideline from the American Academy of Family Physicians andAmerican College of Physicicans.
Annals of Family Medicine. Vol.5, No.1, January/February 2007
![Page 66: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/66.jpg)
Pulmonary CT AngiogramPulmonary CT Angiogram
CT Pulmonary Angiogram can replace pulmonary angiography in patients with non diagnostic V/Q scan and negative leg ultrasound finding
Schwartzman, K., et al.
![Page 67: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/67.jpg)
Barry, P., et al. Current Diagnosis of Venous Thromboembolism in Primary Care: A Clinical Practice Guideline from the American Academy of Family Physicians andAmerican College of Physicicans.
Annals of Family Medicine. Vol.5, No.1, January/February 2007
![Page 68: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/68.jpg)
![Page 69: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/69.jpg)
![Page 70: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/70.jpg)
![Page 71: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/71.jpg)
Chest X-rayChest X-ray
![Page 72: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/72.jpg)
12-Lead ECG12-Lead ECG
![Page 73: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/73.jpg)
Arterial Blood GasArterial Blood Gas
pO2 84.8
pH 7.44pCO2 34.4
HCO3 23.3
O2 Sat. 96.8
B.E. -0.1Total CO2 24.3
RR 32Condition 2 LPM/NC
![Page 74: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/74.jpg)
WarfarinWarfarin
Has a long half life in plasma (36 hours)Reduction of all vitamin K-dependent coagulation proteins into the therapeutic range requires 4-5 days of therapyHeparin therapy should be overlapped w/ warfarin for a minimum of 5 days & continued until the INR has been w/in the therapeutic range (2.0 to 3.0) for at least 2 consecutive days
Buller, HR, Agnelli, G, Hull, RD, et al. Antithrombotic therapy for venousthromboembolic disease: The 7th ACCP Conference on Antithrombotic
and Thrombolytic Therapy. Chest 2004; 126:401S.
![Page 75: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/75.jpg)
Unfractionated Heparin (UFH)Unfractionated Heparin (UFH)
IV UFH should be administered by continuous infusionIntermittent IV bolus dosing has been associated with an increased incidence of major bleeding
Levine, MN, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:287S.
![Page 76: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/76.jpg)
Unfractionated Heparin (UFH)Unfractionated Heparin (UFH)
Achieve a critical therapeutic level of heparin w/in the 1st 24 hrs. of treatment
Inadequate initial heparin therapy increases the probability of recurrent thromboembolism for at least 3 months
Hull, RD, et al. The importance of initial heparin treatment on long-term clinical outcomes of
antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med 1997; 157:2317.
![Page 77: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/77.jpg)
![Page 78: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/78.jpg)
![Page 79: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/79.jpg)
Repeat Arterial Blood GasRepeat Arterial Blood Gas
pO2 93
pH 7.43pCO2 43.4
HCO3 28.8
O2 Sat. 98.3
B.E. 4.03Total CO2 30.1
RR 32Condition 2 LPM/NC
![Page 80: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/80.jpg)
CBC MonitoringCBC Monitoring
Day 0 1st HD 4th HD 5th HD 7th HD 9th HD 11th HD 13th HD
Hgb 13.7 11.9 7.4 11.2 9.7 9.5 11.3 11.4
Hct 41.6 35.9 22.7 35 30 29.8 34.8 35.7
WBC 10,250 24,090 19,780 17,920 10,220 9,550
Segm 86 74 82 85 82 83
Lympho 6 7 9 7 7 9
Platelet 353T 333T 367T 490T 823T 805T
2 3
![Page 81: Morbidity and Mortality Conference Maria Monina T. Clauna, M.D. May 24, 2007 Makati Medical Center](https://reader038.vdocuments.us/reader038/viewer/2022110210/56649e8b5503460f94b9093f/html5/thumbnails/81.jpg)
Repeat Chest X-rayRepeat Chest X-ray